Novacea, Inc. - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Novacea, Inc.. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Novacea, Inc.. The Group's principal activity is that of a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Its product portfolio features three clinical-stage oncology product candidates: DN-101, vinorelbine oral and AQ4N. Its lead product candidate, DN-101, is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer. AQ4N is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy. It also seeks to develop anti-cancer agents that may reduce the toxicities associated with current treatments. Trademarks include Asentar and We Can. In May 2007, the Group signed an exclusive License, Development and Commercialization Agreement with Schering Corporation for the development and commercialization of 'Asentar.'

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report